April 5, 2018 / 12:26 PM / 3 months ago

BRIEF-Antares Pharma Says FDA Accepts Resubmission To CRL For Xyosted NDA

April 5 (Reuters) - Antares Pharma Inc:

* ANNOUNCED FDA ACKNOWLEDGED RECEIPT OF RESUBMISSION TO CRL RECEIVED IN CONNECTION WITH XYOSTED NEW DRUG APPLICATION

* FDA CONSIDERED RESUBMISSION A COMPLETE, CLASS 2 RESPONSE & HAS ASSIGNED USER FEE GOAL DATE OF SEPT. 29, 2018 Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below